HCW Biologics Inc. Common Stock

Day range

$1.10 – $1.18

Open

$1.17

Prev close

$1.17

Volume

25.17K

Market cap

$2.62M

Shares out

2.24M

P/E

—

P/S

0.39

P/B

0.35

P/FCF

—

ROE

-288.3%

ROA

-80.0%

Debt/Equity

0.88

Div yield

0.00%

As of Oct 23, 2026

• Private placementSep 24, 2026

  On September 23, 2026, HCW Biologics Inc. entered into a Securities Purchase Agreement with an existing institutional investor, pursuant to which the Company agreed to issue and sell an aggregate of 903,614 units at a purchase price of $1.6599 per Unit. The Investors represented that they are "accredited investors" and the transaction was made in reliance on Section 4(a)(2) and Rule 506(b) of Regulation D.

• Shareholder proposal outcomeSep 10, 2026

  "After considering stockholder feedback, the board of directors of the Company decided not to seek stockholder approval of Proposal No. 2 in the Original PRE 14A, which would have sought stockholder approval of an amended performance-based equity plan for the Company's eligible officers, directors and employees, and to remove that proposal through the Amendment."

• Supply or distribution agreementSep 8, 2026

  On September 4, 2026, HCW Biologics Inc. entered into an Exclusive Distribution Agreement with Akron Biotech for the distribution of the Company's commercial-ready molecule, HCW11-006, throughout the world, excluding the People's Republic of China, for a term of five years from the closing date unless terminated earlier.

• Internal control weaknessAug 14, 2026

  Management evaluated the effect of the error and restatement on the Company's disclosure controls and procedures and internal control over financial reporting and concluded that a material weakness existed related to the ineffective operation of the Company's technical accounting review control over complex warrant instruments and financing transactions, including the evaluation of relevant contractual provisions and related legal interpretations, at a sufficient level of precision.

• Private placementJul 29, 2026

  On July 29, 2026, HCW Biologics Inc. (the "Company") entered into a Securities Purchase Agreement (the "Purchase Agreement") with certain accredited investors (each, an investor, and collectively, the "Investors"), pursuant to which the Company agreed to issue and sell an aggregate of 618,682 units (the "Units"), with each Unit consisting of (i) one share of the Company's common stock, par value $0.0001 per share (the "Common Stock"), or, in lieu thereof, one pre-funded warrant to purchase one share of Common Stock (the "Pre-Funded Warrants"), and (ii) the right to receive one common stock purchase warrant (the "Common Warrants") to purchase one share of Common Stock upon, and subject to, stockholder approval of the issuance of the Common Warrants.

Days to cover

1.0

Short interest

60.94K

Avg volume

1.35M

As of Sep 30, 2026 · reported to FINRA twice monthly.

• HCW Biologics Entered an Exclusive Distribution Agreement with Akron Biotech to Commercialize HCW11-006 as Reagent Used to Support Production of Highly Functional Human CAR-T Cells
  positiveGlobeNewswire Inc.· Sep 8, 2026
• HCW Biologics’ TGF-β Trap and IL-15 Fusion is a Novel Moiety to Enhance Immunotherapeutic Activity against Diseased Cells
  positiveGlobeNewswire Inc.· Aug 25, 2026
• HCW Biologics Announces 1-for-6 Reverse Stock Split Effective on June 30, 2026
  neutralGlobeNewswire Inc.· Jun 26, 2026
• HCW Biologics Announces Pricing of $1.5 Million Follow-On Offering Priced At-The-Market Under NASDAQ Rules
  neutralGlobeNewswire Inc.· Feb 17, 2026
• HCW Biologics Inc. (NASDAQ: HCWB) Participates in Virtual Investor “What This Means” Segment
  positiveGlobeNewswire Inc.· Oct 22, 2025